Загрузка...
The Use of Exenatide in Islet Transplant Recipients with Chronic Allograft Dysfunction: Safety, Efficacy and Metabolic Effects
BACKGROUND: A current limitation of islet transplantation is reduced long term graft function. The glucagon like peptide-1 (GLP-1) receptor agonist, exenatide (Byetta(®), Amylin Pharmaceuticals, CA) has properties that could improve existing islet function, prevent further loss of islet mass and pos...
Сохранить в:
| Главные авторы: | , , , , , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
2008
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2772201/ https://ncbi.nlm.nih.gov/pubmed/18622276 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/TP.0b013e31817c4ab3 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|